Last reviewed · How we verify

NCT04880681

Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle

Status unknown NA Last updated 1 May 2023
What this trial tests

NA trial testing Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator. in Prostate Cancer (Diagnosis) in 60 participants. Status unknown.

Timeline
17 May 2021
Primary endpoint
30 December 2023
28 February 2024

Quick facts

Lead sponsorRegion Skane
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeother
Enrollment60
Start date17 May 2021
Primary completion30 December 2023
Estimated completion28 February 2024
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Region Skane — full company profile →

Who can join

40 and older, male only, with Prostate Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patient-blinded randomized controlled trial evaluating length and quality of prostate biopsies taken by a novel biopsy needle.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prostate Cancer (Diagnosis)

Currently open trials in the same condition.

Other Region Skane trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04880681.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing